I count I think 6 phase 3 studies for Gilead in HCV covering across the genotypes, take a look at the 2 links above listing the various phase 3 studies. The ELECTRON Study is a phase 2 of about 94 patients looking at both treatment-naives & null responders with each of 3 treatment arms for 12 weeks therapy: GS7977+Rbv, GS7977+GS5885 (NS5A)+Rbv and GS7977+GS9669 (non-nuc)+Rbv. These were 90% Gt1a patients without cirrhosis, phase 3 will include cirrhotics. You can view the ELECTRON slide presentation here at EASL with the link above. Here is the results slide just below showing 100% in naives (25/25) with the 3-drug regimen of GS7977+GS5885+Rbv & 100% in nulls with the same regimen, phase 3 ION studies will look at with & without Rbv with the coformulation of GS7977+GS5885. You can see this study also looked at GS7977+GS9669 (non-nuc)+Rbv with 92% SVR in naives (23/25) & 3/3 SVR in nulls all with 12 weeks, ION-2 will look at treatment-experienced with 12 and 24 weeks therapy.
